Vaxart Faces Critical Nasdaq Deadline Amid Financial Pressures
11.10.2025 - 08:27:04Financial Performance: Mixed Signals Emerge
Vaxart Inc. finds itself navigating multiple challenges simultaneously as its stock trades at just $0.34 per share. The biotechnology firm confronts substantial selling pressure alongside an existential threat: potential delisting from the Nasdaq exchange. With an October 17 deadline rapidly approaching, the company must urgently address listing compliance requirements.
Recent quarterly results revealed dramatic revenue growth, surging from $6.4 million to $39.7 million. However, this positive development was tempered by research expenditures that ballooned to nearly $50 million. The company’s cash position of $26.3 million raises questions about its financial runway, with current resources potentially lasting only into the first quarter of 2026.
Key financial indicators:
* Revenue demonstrates significant expansion
* Research costs have increased substantially
* Limited cash reserves create operational constraints
